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ABSTRACT

Disturbances in melatonin—the neurohormone that signals environmental
darkness as part of the circadian circuit of mammals—have been implicated in various
psychopathologies in humans. At present, experimental evidence linking prenatal
melatonin signaling to adult physiology, behavior, and gene expression is lacking. We
hypothesized that administration of melatonin (5 mg/kg) or the melatonin receptor
antagonist luzindole (5 mg/kg) to rats in utero would permanently alter the circadian
circuit to produce differential growth, adult behavior, and hippocampal gene expression
in the male rat. Prenatal treatment was found to increase growth in melatonin-treated
animals. In addition, subjects exposed to melatonin prenatally displayed increased
rearing in the open field test and an increased right turn preference in the elevated plus
maze. Rats administered luzindole prenatally, however, displayed greater freezing and
grooming behavior in the open field test and improved learning in the Morris water maze.
Analysis of relative adult hippocampal gene expression with RT-PCR revealed increased
expression of brain-derived neurotrophic factor (BDNF) with a trend toward increased
expression of melatonin 1A (MEL1A) receptors in melatonin-exposed animals whereas
overall prenatal treatment had a significant effect on microtubule-associated protein 2
(MAP2) expression. Our data support the conclusion that the manipulation of maternal
melatonin levels alters brain development and leads to physiological and behavioral
abnormalities in adult offspring. We designate the term circadioneuroendocrine (CNE)
axis and propose the CNE-axis hypothesis of psychopathology.
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INTRODUCTION

The Circadian Circuit

Melatonin, the hormone that encodes information about daily rhythms in
mammals, has been implicated in various psychopathologies in humans. Changes in
melatonin secretion have been found in depression (for a review see Srinivasan et al.
2006), Alzheimer’s disease and Parkinson’s disease (for a review see Srinivasan et al.
2006), schizophrenia (for a review see Sandyk et al. 1990), and other psychiatric illnesses
(for a review see Pacchierotti et al. 2001). Despite indications that this neurohormone is
important for proper brain function, the physiology of its impact on the brain is not
clearly understood.
Melatonin release displays rhythmic behaviors with a period of approximately 24
hours in response to the circadian pacemaker (Figure 1) (Refinetti 2006). In mammals,
the circadian pacemaker is controlled by clock genes in the suprachiasmatic nucleus
(SCN) of the hypothalamus (Figure 2) (for a review see Okamura 2004). Daily
fluctuations in the activity of the SCN can be altered by light from the environment via
projections from retinal ganglion cells along the retinohypothalamic path. In addition,
outputs from the SCN project indirectly to the pineal gland, the primary brain region
responsible for the production of melatonin. The pineal releases melatonin with a nightly
peak in response to input from the SCN to impact cells throughout the body. In addition,
the SCN responds to melatonin secretion by the pineal via melatonin receptors in
membranes of its cells. This feedback loop involving visual inputs and melatonin
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Figure 1. Simplified schematic of the circadian circuit responsible for daily rhythm
of activity in mammals (Adapted from Refinetti 2006). Light at the retina induces
signaling at glutamatergic synapses by retinal ganglion cells projecting to the
suprachiasmatic nucleus along the retinohypothalamic path. In addition, the
intergeniculate leaflet of the thalamus receives signals from the retina and relays this
information to the suprachiasmatic nucleus via neuropeptide Y synapses, and the raphe
nuclei also communicate other environmental information to the suprachiasmatic nucleus
via serotonergic synapses. The suprachiasmatic nucleus, which contains the primary
circadian molecular clock, processes these inputs and elicits release of melatonin by the
pineal gland in addition to projecting to other brain regions. Melatonin produced by the
pineal gland is released into circulation in the blood and cerebrospinal fluid in response to
this stimulation. In addition to feeding back to the suprachiasmatic nucleus, melatonin
also modulates release of growth hormone by the pituitary gland by an as yet unidentified
mechanism. Both melatonin and growth hormone affect the hippocampus and other brain
regions in a circadian fashion.
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Figure 2. Simplified model of the oscillatory molecular clock gene network in cells
of the suprachiasmatic nucleus of mammals (adapted from Okamura 2004). The
mPER1 and mPER2 genes are expressed along with other ccg (clock controlled genes) to
produce various proteins that dimerize. These mPER-mCRY dimers inhibit CLOCKBMAL1 protein dimer function and indirectly promote expression of the Bmal1 gene.
Over several hours, mPER1 and mPER2 expression declines, but concentration of
CLOCK-BMAL1 dimers gradually begins to rise again. These dimers bind E-boxes and
promote expression of mPER1, mPER2, and ccg to complete the feedback loop.
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secretion entrains the sleep/wake cycle of mammals to their environment. We shall refer
to the neurohormonal feedback loop involving the SCN, pineal, and associated structures
as the circadian circuit.
Within cells of the pineal gland in mammals, melatonin is produced by a multistep biosynthetic pathway (Figure 3) (for reviews see Axelrod 1970; Simonneuax et al.
2003). 5-Hyrdoyxytryptophan is synthesized from tryptophan by tryptophan hydroxylase
(TPOH). Aromatic amino acid decarboxylase (AAAD) converts 5-hydroxytryptophan to
serotonin, and acetylation of serotonin by arylalkylamine N-acetyltransferase (AA-NAT)
produces N-acetylserotonin. Finally, hydroxyindole-O-methyltransferase (HIOMT)
produces melatonin from N-acetylserotonin. Interestingly, children with autism spectrum
disorder and their unaffected parents were more likely to have a mutation in the HIOMT
gene and concomitant reduction in melatonin production compared to controls (Melke et
al. 2008). The synthetic melatonin receptor antagonist luzindole has a structure similar to
that of melatonin but contains an additional benzyl group (Dubocovich 1988).

Melatonin, Development, and Pathology

Melatonin produced by the circadian circuit has broad impacts throughout the
body. There is evidence that melatonin may influence secretion of growth hormone by
the pituitary by an as yet unidentified mechanism. The nightly peak in melatonin may be
involved in the timing of growth hormone production (Brandenberger et al. 2004).
Human subjects administered 10 mg of melatonin showed an increase in serum growth
hormone in response to the drug (Valcalvi et al. 1993), however, earlier studies found
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Figure 3. Structures of molecules in the melatonin biosynthetic pathway in the
pineal gland (a) (adapted from Simonneaux et al. 2003) and of the melatonin
receptor antagonist luzindole (b). Structures of all molecules shown contain indole
groups composed of a pyrrole ring attached to a benzene ring. In pinealocytes, 5hydroxytryptophan is synthesized from tryptophan by tryptophan hydroxylase (TPOH).
Aromatic amino acid decarboxylase (AAAD) then converts 5-hydroxytryptophan to
serotonin, and acetylation of serotonin by arylalkylamine N-acetyltransferase produces
N-acetylserotonin. Finally, hydroxyindole-O-methyltransferase (HIOMT) produces
melatonin from N-acetylserotonin. The synthetic melatonin receptor antagonist luzindole
has a structure similar to that of melatonin but contains an additional benzyl group.
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that melatonin has an inhibitory effect on growth hormone release in both humans
(Smythe et al. 1974 a) and rats (Smythe et al. 1973). Insertion of melatonin implants in
3- to 4-month old heifers for 5 weeks in early summer induced precocious puberty in
heifers (Tortonese et al. 1992), and pineal gland tumors that reduce melatonin secretion
from the pineal gland during development elicited precocious puberty in humans (Cohen
et al. 1964). Interestingly, precocious puberty was found to be a predictor for a subtype
of schizophrenia in women (Cohen et al. 1999).
Because melatonin release by the circadian circuit is influenced by light,
melatonin secretion is affected by seasonal variation in light patterns. Seasonal changes
in melatonin profiles regulate reproduction in many mammals (for a review see Arendt
1998). Nightly peaks of melatonin in adult (Luboshitzky et al. 1998) and infant (Sivan et
al. 2001) humans may be greatest when photoperiods are the longest. Moreover, risk of
developing schizophrenia is greater for individuals born during winter and early spring at
greater latitudes (Davies et al. 2003), when maternal nightly melatonin secretion during
the third trimester is lowest. A seasonal correlation between birth date and adult disease
has been found in various studies on psychiatric disorders in humans (for a review see
Torrey et al. 1997). Explanations for this variation have been proposed, but the causes
have yet to be identified.
Evidence in various animal models suggests a role for melatonin in brain
development. Reduced prenatal melatonin by pinealectomy was associated with
increased signs of depression in Siberian hamster offspring (Workman et al. 2008). In
addition, studies using cell cultures suggest a possible role for melatonin during
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embryonic development. Melatonin inhibits apoptosis in U973 human monocytic cells
(Radogna et al. 2006), and it has been found to reduce damage to rat hepatoma cells by
free radicals via its function as a free radical scavenger (Kimball et al. 2008). In addition
to its effects on cell maintenance, melatonin has been found to affect cell growth.
Melatonin promotes polymerization of tubulin and production of neurites in cells in vitro
(Meléndez et al. 1996). Melatonin also increases the rate of cell proliferation in zebrafish
embryos (Danilova 2004), and it promotes differentiation but not proliferation of adult
hippocampal neurons in culture (Moriya et al. 2007).
Melatonin receptors are distributed in various brain regions in the human fetus,
including the hypothalamus, thalamus, and meninges (Thomas et al. 2002) and are more
widely distributed in the brains of fetal and neonatal rats compared to adults (Zitouni et
al. 1995). Moreover, maternal pinealectomy reduces melatonin receptor number in the
SCN, pituitary, and thalamic structures of rat neonates (Zitouni et al. 1995).
Signaling via these melatonin receptors in the fetal brain may cause permanent
changes in the circadian circuit. Cocaine was found to cause long-term changes in
expression of clock genes in zebrafish embryo, and this effect was reversed by
administration of melatonin (Shang et al. 2007). In addition, prenatal melatonin
reduction was found to alter the clock gene expression in the SCN of capuchin monkeys
(Torres-Farfan et al. 2006) and treatment with prenatal melatonin altered postnatal
photoperiodic traits of young meadow voles (Lee et al. 1989). These studies indicate that
melatonin concentrations in utero may affect the function of the circadian circuit not only
in the womb but also after birth.
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Melatonin is also important in the brain postnatally, and melatonin receptors have
been found in the adult rat hippocampus (Mushoff et al 2002). In fact, melatonin
administration altered long-term potentiation and ultimately synaptic plasticity of
hippocampal cells from CD-1 mice (El-Sherif et al 2003) and long-term treatment with
melatonin increased NMDA receptor concentrations in the rat hippocampus (Sutcu et al
2006). Deletion of the gene for the MT2 melatonin receptor in mice produced memory
deficits in habituation to the elevated plus maze (Larson et al 2006) and treatment with
melatonin reduced hippocampal degeneration in a mouse model of Alzheimer’s disease
(Cheng et al 2008). Thus, regular secretion of melatonin in adulthood may contribute to
maintenance of proper hippocampal function.

Hippocampus, Limbic System, and HPA Axis

Changes in hippocampal morphology have been found in various psychiatric
disorders. For example, individuals with autism from ages 2 to 42 years were found to
have reduced volume in the area dentata of the hippocampus (Saitoh et al. 2001), and
three- to four-year-old children with autism have been found to have significant changes
in hippocampal shape by large-deformation high-dimensional brain mapping (Dager et al.
2007). Moreover, enlarged volume of the left hippocampus was identified not only in
children and adults with autism but also in parents of children with autism (Rojas et al.
2004), and changes in hippocampal structure have been found in individuals with
schizophrenia. High-dimensional brain mapping revealed morphological deformations in
regions of the hippocampus projecting to the prefrontal cortex in drug-naïve patients with

13
schizophrenia (Csernansky et al. 1998), whereas Rajarethinam et al. (2001) found no
significant difference in hippocampal size between individuals with schizophrenia and
controls but did find a correlation between shape of left hippocampal subregions and
symptoms in male subjects. Meta-analyses reveal a general reduction in hippocampal
volume in schizophrenia (McCarley et al. 1999; Nelson et al. 1998).
The hippocampus has been identified to have various roles in humans and other
mammals. In elderly human subjects, hippocampal head volume was found to be
negatively correlated with age (Chen et al. 2010). Specifically, right hippocampal tail
volume was connected to spatial memory on the Groton Maze Learning Test, and left
hippocampal volume was associated with deficits in verbal memory. In addition, adult
males ages 18-31 who were more resistant to forgetting in a monetary incentive delay
task displayed greater activation in the left posterior hippocampus via fMRI (Kuhl et al.
2010), and human subjects with amnesia resulting from bilateral hippocampal insult
displayed greater difficulty imagining scenarios compared to controls (Hassabis et al.
2007). A recent review argued for roles of the hippocampus in imagination and
prediction (Buckner 2010). Moreover, the hippocampus has been implicated in spatial
learning across mammalian species (for a recent letter see Amrein et al. 2009; for a
review see El Falougy et al. 2006).
More generally, the hippocampus is considered part of the limbic system, a brain
circuit involved in emotion (for symposium see Nakano 1998; for review see Sapolsky
2003). The limbic system is capable of activating the hypothalamic-pituitary-adrenal
(HPA) axis—the neuroendocrine mediator of the stress response in mammals—in
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response to environmental stimuli (for a review see Engelmann et al. 2004). Within this
circuit, the hypothalamus releases corticotrophin-releasing hormone (CRH) in response to
signals from other brain regions (Figure 4) (for a review see Tsigos et al. 2002) and CRH
elicits release of adrenocorticotropic hormone (ACTH) from the anterior pituitary.
ACTH promotes release of corticosteroids—including cortisol—from the adrenal
cortices, and these corticosteroids inhibit further release of hormones by the
hypothalamus and pituitary.
Dysregulation of the limbic system and HPA axis has been found in various
psychiatric disorders. Patients with resistant schizophrenia were found to have a higher
level of serum cortisol, and these levels were correlated with negative symptoms of the
disorder (Zhang et al. 2005). Women with postpartum depression were found to have
increased ACTH but reduced cortisol relative to controls (Jolley et al. 2007).
Responsiveness of cortisol release to negative events was found to be blunted in
individuals with major depressive disorder, but no basal difference in salivary cortisol
levels was observed (Peeters et al. 2003). Moreover, children with autism showed greater
variability in circadian salivary cortisol profiles relative to controls (Corbett et al. 2008).
Thus, dysregulations of the HPA axis are connected with psychiatric disorders.

Serotonin Receptors

Evidence implicates the HPA axis in regulation of hippocampal serotonin (5hydroxtrypatamine or 5HT) receptors (for a review see Leonard 2005). At present, 14
subtypes of serotonin receptors have been identified in mammals (for a review see
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Figure 4. Simplified schematic of the hypothalamic-pituitary-adrenal (HPA) axis
(adapted from Tsigos et al. 2002). The hippocampus and other regions of the limbic
system elicit release of corticotropin-releasing hormone (CRH) from the hypothalamus in
response to stress. CRH promotes release of adrenocorticotropic hormone (ACTH) by
the anterior pituitary, and ACTH causes the adrenal cortices to release corticosteroids
including cortisol (CORT) into the bloodstream. CORT inhibits further release of ACTH
and CRH in addition to impacting the hippocampus and other brain regions.
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Nichols et al. 2008). All serotonin receptor subtypes except for 5HT3 receptors are Gprotein-coupled receptors (GPCRs). In particular, serotonin GPCRs are of the type A
family of rhodopsin-like receptors (Fredriksson et al. 2003) while the 5HT3 receptor is a
ligand-gated ion channel (Maricq et al. 1999) (for a review of 5HT receptors see Barnes
et al. 1999).
Research also indicates potential differential involvement of serotonin (5hydroxytryptamine or 5HT) receptor subtypes in psychopathology. Serotonin receptor
concentrations have been found to be altered in the hippocampus of individuals with
severe psychiatric illness (Knable et al. 2004). In particular, it was found that 5HT1A
expression was lower in the hippocampus of individuals with major depressive disorder
while subjects with schizophrenia and bipolar disorder had increased 5HT1B expression
and decreased 5HT2A expression in the hippocampus (López-Figueroa et al. 2004).
Since melatonin may also play a role in these psychopathologies, investigation of the
effects of melatonin on the serotonergic system is warranted.
Corticosteroids have been found to be involved in the regulation of hippocampal
5HT1A receptor expression. In particular, adrenalectomy of Sprague-Dawley rats
increased 5HT1A mRNA expression in the hippocampus 1 day and 7 days after surgery
and this change could be prevented by administration of cortisol at surgery (Chalmers et
al. 1993). Activation of 5HT1A receptors in the rat hippocampus inhibits adenylyl
cyclase (Okada et al. 1989), and administration of serotonin and the 5HT1A receptor
agonist NAN-190 to Wistar rat hippocampal CA1 cells in culture resulted in reduced
excitatory post-synaptic potentials (EPSPs) (Schmitz et al. 1995). 5HT1A agonists were

18
unable to elicit hyperpolarization in mouse hippocampal neurons from mice lacking the
gene for G protein-coupled inwardly rectifying K+ channel 2 (GIRK2) (Luscher et al.
1997). In addition to their involvement in serotonergic transmission, 5HT1A receptors
are also involved in noradrenergic transmission in the hippocampus. In particular,
activation of hippocampal 5HT1A receptors elicited activation of noradrenergic pathways
postsynaptically in rats (Hajós-Korcsok et al. 1999). In addition, the increase in
acetylcholine release in response to administration of the 5HT1A agonist 8-OH-DPAT
was prevented by administration of the 5HT1A receptor antagonist WAY-100135 (Nakai
et al. 1998).
In contrast, corticosteroids were not found to regulate expression of 5HT1B
mRNA in adrenalectomized male Sprague-Dawley rats (Neumaier et al. 2000). In CHO
cells, 5HT1B receptors were found to inhibit adenylyl cyclase and increase activity of
ERK2 (Mendez et al. 1999). Moreover, signaling via 5HT1B receptors reduced serotonin
release in the rat hippocampus in vivo (Martin et al. 1992), suggesting a role for this
receptor subtype as an autoreceptor. This receptor subtype has also been found to inhibit
cholinergic pathways in the rat hippocampus (Maura et al. 1986).
5HT2A receptors have distinct roles in the stress response. NIH3T3 fibroblasts
expressing rat 5HT2A receptors were found to release the endocannabinoid 2arachidonoyl glycerol via activation of phospholipase C (PLC) (Parrish et al. 2006). In
cultured astrocytes from newborn rat cerebral cortex, 5HT2A receptor activation elicited
Ca2+ influx via ligand-gated ion channels (Hagberg et al. 1998). Moreover, hippocampal
granule cells from male Sprague-Dawley rats administered serotonin induced
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depolarization and this response was reduced by the 5HT2A receptor antagonist MDL
100,907 (Piguet et al. 1994). The reduction of BDNF expression in the hippocampus
observed in response to immobilization stress in male Sprague-Dawley rats was also
attenuated by administration of the 5HT2A receptor antagonist MDL, 100,907 prior to
testing (Vaidya et al. 1999).

Brain Derived Neurotrophic Factor
Brain derived neurotrophic factor (BDNF) is a protein signaling molecule known
for its promotion of growth and survival of neurons in the hippocampus (for a review see
Binder et al. 2004). Activation of BDNF’s tropomyosin-related kinase B receptor (TrkB)
increased activity of synaptic proteins in rat cortical neurons in culture, and depletion of
BDNF or inhibition of its receptor prevented this effect (Jia et al. 2008). Activation of
TrkB was also found to be required for long-term synaptic facilitation in Aplysia (Sharma
et al. 2006). Reduced levels of BDNF have been found in the serum of patients with
schizophrenia (Toyooka et al. 2002), and BDNF has also been implicated in depression
(for a review see Castrén et al. 2010).

Microtubule-Associated Protein 2

Microtubule-associated protein 2 is (MAP2) is one of several proteins involved in
the cytoskeletal organization in dendrites (for a review see Farah et al. 2008), and
increased expression of MAP2 has been found in the hippocampus of individuals with
schizophrenia (Cotter et al. 2000). Dendritic size was found to be reduced in cerebellar
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tissue from MAP2-knockout mice, and cells from these animals displayed reduced PKA
signal transduction (Harada et al. 2002). Induction of long-term potentiation (LTP) in
various hippocampal pathways increased expression of MAP2 mRNA (Roberts et al.
1998), and application of NMDA—a glutamate agonist mediating LTP induction—to
hippocampal granule cells also elicited increased expression of MAP2 mRNA in
dendrites (Johnston et al. 1994).

Spinophilin

Another dendritic protein associated with the cytoskeleton, spinophilin or
neurabin 2, is localized in the heads of dendritic spines (for a review see Sarrouilhe et al.
2006). Phosphorylation of spinophilin by protein kinase A (PKA) in vitro elicits its
dissociation from actin filaments (Hsieh-Wilson et al. 2003). Spinophilin also blocks a
binding site of protein phosphatase 1 (PP1) without blocking its active site to direct the
enzyme to particular substrates (Ragusa et al. 2010). Spinophilin-knockout mice showed
reduced ability of PP1 to regulate AMPA and NMDA receptors resulting in inhibition of
long-term depression in the caudotoputamen and reduced hippocampal size (Feng et al.
2000). This study also found increased numbers of dendritic spines in hippocampal cells
from young spinophilin knockout mice relative to controls. Interestingly, patients with
schizophrenia and mood disorders showed similar reductions in spinophilin mRNA in the
hippocampus via in situ hybridization (Law et al. 2004).
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Growth Hormone Receptor

Growth hormone receptor (GHR) is a cell membrane receptor (for a review see
Postel-Vinay et al. 1995). Fusion of ligand to this receptor elicited receptor dimer
formation and signal transduction in CHO cells (Wilkinson et al. 2007). Growth
hormone administration enhanced excitatory post-synaptic potentials in slices of
pyramidal neurons from the CA1 region of the hippocampus of male Sprague-Dawley
rats (Mahmoud et al. 2006). Although circulating growth hormone is secreted from the
anterior pituitary, growth hormone production has also been detected in the hippocampus
of Sprague-Dawley rats of both sexes, and growth hormone mRNA levels in this brain
region increase in response to stress (Donahue et al. 2006).

Melatonin Receptors

Two primary types of melatonin receptors have been identified in various
mammalian tissues, including the hippocampus (for a review see Pandi-Perumal et al.
2008). Both MEL1A (Brydon et al. 1999) and MEL1B (Reppert et al. 1995) receptors
are from the G-protein-coupled-receptor family and are coupled to inhibition of adenylyl
cyclase. The C-terminal domain of both receptor subtypes is necessary for internalization
(Sethi et al 2008). Evidence suggests a role for melatonin receptors in hippocampal
pathology. For example, MEL1A receptor expression increased (Savaskan et al. 2002)
and MEL1B receptor expression decreased (Savaskan et al. 2005) in the hippocampus of
elderly patients with Alzheimer’s disease relative to controls.
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Hypothesis

Our study was designed to test the hypothesis that increasing or decreasing
prenatal melatonin signaling in male rattus norvegicus affects growth, hippocampal mass,
anxiety- and depression-related behaviors, spatial learning, and memory in adult rats. In
addition, we hypothesized that prenatal treatment would produce differential adult
hippocampal mRNA expression profiles for genes involved in regulating dendritic
structure and function as well as neuron maintenance and cognitive function.

MATERIALS AND METHODS

Animals and Tissue Collection

Eleven pregnant Sprague-Dawley dams were obtained from Hilltop Laboratories
in two cohorts and randomly assigned to three treatment groups. Three of the dams were
injected with vehicle containing 50% (volume/volume) sterile, filtered DMSO (Sigma
Aldrich, St. Louis, MO) in distilled water (i.e. 0.1 mL DMSO/kg dam per day), four were
injected with 5 mg/kg melatonin (N-Acetyl-5-methoxytryptamine) (Sigma Aldrich), and
four were injected with 5 mg/kg luzindole (N-Acetyl-2-benzyltryptamine) (BA
Chemicals, London, UK), a nonselective melatonin receptor antagonist (Dubocovich
1988). All drugs were administered subcutaneously immediately before the dark cycle at
1600 to 1800 hours as this is the time of maximal response to the drugs (Golombek et al.
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1993). Injections were given for 5 days from days 14 to 18 of gestation at a volume of
0.05 to 0.06 mL per day. Dams were housed individually.
All animals were kept under controlled lighting (0600 to 1800 hours) and
temperature (23ºC) with food and water ad libitum. Food consisted of standard rat chow
providing 3.85 kcal/g (dry wt), 19.2 gm% protein, 67.3 gm% carbohydrate, and 4.3 gm%
fat (10 kcal% fat D12450B; Research Diets, New Brunswick NJ). At birth, offspring
were weighed and litters were culled to 10 young per dam while maintaining all healthy
males. At weaning on postnatal day 21, male offspring were housed in pairs with a
conspecific from the same treatment group. Body mass per rat and food intake per cage
were measured approximately every 5 to 7 days from weaning until sacrifice. After 120
days, half the animals were sacrificed at 0000 hours, and the rest were sacrificed at 1200
hours. The animals were momentarily placed in a pre-charged chamber of CO2 and
subsequently decapitated by guillotine. Immediately following sacrifice, right and left
hippocampi were quickly dissected from each brain, weighed, and rapidly frozen with
liquid nitrogen; and abdominal, retroperitoneal, and gonadal fat was excised. This
research was conducted in accordance with the NIH Guide for Care and Use of
Laboratory Animals, and all animal protocols used have been reviewed and approved by
the Animal Care and Use Committee of Bucknell University.

Behavioral Measures

After postnatal day 90, a staggered behavioral testing regimen was begun on adult
subjects. Animals from cohort one were subjected to tests in the following order: open
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field test, forced swim test, elevated plus maze, and Morris water maze; cohort two
subjects were tested as follows: Morris water maze, elevated plus maze, forced swim test,
open field test. All behavioral tests were recorded, and data was measured by computer
with tracking software (ANY-Maze, Stoelting, Wood Dale IL). Time inactive was found
by subtracting time mobile, time rearing, and time grooming from total time. Turn
preference was calculated as follows:
Clockwise Turns  1


Turn Preference  log 

 Counterclo ckwise Turns  1 

(1)

Forced swim test. The forced swim test is a measure of learned helplessness. The
learned helplessness hypothesis states that ―when events are uncontrollable the organism
learns that its behavior and outcomes are independent‖ (Maier et al. 1976). This
behavioral construct includes ―motivational,‖ ―cognitive,‖ and ―emotional‖ components.
Porsolt et al. (1978) developed the forced swim test to measure learned helplessness. In
the forced swim test, immobility in response to placement in an inescapable tank of water
as evidenced by free floating is considered a sign of learned helplessness (West 1990).
Although learned helplessness is a construct with respect to learning, changes in
performance on learned helplessness tasks have been connected to depression (Sherman
et al. 1982).
The protocol of Porsolt et al. (1978) was modified slightly for this study. Animals
were placed in translucent white plastic cylinders (45 cm height 35 cm diameter)
containing 30 cm water (25 ±2 °C) in 160 lux light for 15 minutes without recording, and
the tank was emptied between subjects. Twenty-four hours later, animals were similarly
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placed in tanks, and behavior was recorded for 5 minutes. Time immobile was
determined by tracking software at 50% sensitivity, and total distance travelled was also
used as an indicator of immobility (Hedou et al. 2001).
Open field test. The open field test was originally created by Calvin Hall as a
measure of fearfulness (Walsh et al. 1976). In this test, the response of animal subjects to
an open space from which they cannot escape is measured. The test has been considered
a measure of both ―emotionality‖ and ―exploratory behavior‖, although other constructs
have been developed (Maier et al. 1988). In addition, habituation of behavior in the
testing environment occurs upon multiple trials, so learning is also involved (Bolivar et
al. 2000). The open field test is frequently used in pharmacological studies for the
measurement of anxiety (Choleris et al. 2001, Prut et al. 2003, Ramos et al. 1997),
although measures of general locomotor activity can also be obtained from the test
(Maier et al. 1988). The use of the test as a measure of anxiety is evidenced by the
effects of anxiety drugs on behavior of rodents in the testing arena (Choleris et al. 2001).
Rats spend more time in the center zone and less time in thigmotaxis (staying near the
walls of the test arena) if they are less anxious (Prut et al. 2003). However, responses
upon repeated trials can vary by rat strain (Bolivar et al. 2000).
A black testing arena (100 cm x 100cm x 40 cm) with an open top was used
(Ramos et al. 1997). Light reaching the arena was 65 lux at the center, 45 lux at the
middle of the sides, and 30 lux in the corners. Although various colors ranging from
white to black have been used for the arena (Walsh et al. 1976), black was chosen for
greater contrast of the rat with background (Walsh et al. 1976). Although rats can be
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placed in either the center or a corner of the arena at the start of the procedure, we placed
them in the center (Ramos et al. 1997). The arena was divided by the software into 25
squares: 16 outer squares and 9 inner squares (Figure 5a). While behavior has been
recorded for various lengths of time, we did so for 5 minutes (Ramos et al. 1997). While
tracking software recorded most measures, human observers documented rearing and
grooming behavior during testing using ―keys‖ within the software package. Immobility
detection was set at 75% sensitivity.
Elevated plus maze. The elevated plus maze is commonly used as a measure of
anxiety in rodents (Hogg 1996). Anxiety is measured by decreased entries to the open
arms of the apparatus. In particular, the decreased height or absence of walls on the open
arms produces a fear response (Rodgers et al. 1997). Moreover, time on open arms
increases in response to anxiolytic drugs (Rodgers et al. 1997). Others, however, have
also included an approach/avoidance construct in measuring behavior in this test (Wall et
al. 2001) by considering entries to the center of the apparatus.
The protocol of Walf et al. (2007) was used with modifications. Animals were
placed in the center of the plus sign-shaped testing arena (arms 50cm long by 10 cm side
with a 5 mm railing on the open arms) constructed of fiberboard coated with black acrylic
paint and elevated 50 cm from the floor (Figure 5b). Light reaching the apparatus was 13
lux at the center, 25 lux on the open arms, and 3.5 lux in the closed arms. Behavior of
animals was recorded for 5 minutes with human observer present in the room behind a
curtain. Grooming and rearing behavior were recorded real-time by human observer
using the tracking software package, and immobility detection was set at 75% sensitivity.
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Figure 5. Diagrams of testing arenas used for the open field test (a), elevated plus
maze (b), and Morris water maze (c). The open field testing arena was divided into 25
squares with center zone and corner regions (a). The elevated plus maze testing arena
was divided into two closed arms with walls, two open arms without walls, and a central
platform zone (b). The Morris water maze testing arena was divided into quadrants with
cardinal directions, and a hidden platform was located at the center of a memory region
zone (c).
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Animals that fell off the apparatus were returned to it and allowed to complete the testing,
but data from these subjects was excluded from analysis (Walf et al. 2007). Before each
trial, the maze was cleaned with water containing detergent and allowed to dry.
Morris water maze. The Morris water maze was developed by Richard G.M.
Morris for the testing of spatial learning and memory in rats. In particular, lesions in the
various brain regions—including the hippocampus—impair performance on this test
(d’Hooge et al. 2001). In addition, the Morris water maze has also been used to measure
cognitive deficits in models of a variety of neuropsychiatric disorders (d’Hooge et al.
2001).
The protocol of Vorhees et al. (2006) was used with the modifications. A
platform (19.5cm x 19.5 cm x 19.5 cm black cinderblock) was placed in a tank (58 cm
height, 168cm diameter) painted black (Figure 5c). At the center of the apparatus, light
was 75 lux; at the walls, light was approximately 35 lux. Cardinal coordinates were
arbitrarily chosen so that the platform was located in the NW quadrant of the tank. The
tank was filled with water at 25 ±2 °C at the beginning of each testing day to 4 cm above
the top of the cinderblock platform and emptied upon completion of all tests. Geometric
patterns were placed on three walls of the testing room as visual cues. During the 5 days
of the learning phase of the test, animals were placed in the tank facing the wall at one of
each of the cardinal coordinates for 4 trials in a predetermined, randomly-selected order
by cohort. Latency to platform was recorded by tracking software. A trial ended when
the rat remained on the platform for 2 seconds or after 120 seconds. Animals that did not
find the platform in 120 seconds were placed on the platform. Subjects were allowed to
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rest on the platform for 15 seconds before the subsequent trial. If a rat did not remain on
the platform, it was placed back on the platform repeatedly for the duration of 15
seconds. Latencies for the 4 trials for per day were averaged. Forty-eight hours after the
completion of the learning phase of the test, animals were returned to the tank after
removal of the platform for one trial. Preference for the region of the former location of
the platform was recorded for one 30-second trial in order to test memory retention.

RNA Isolation, RT-PCR, and Data Analysis

Total RNA was extracted from the left hippocampus of each subject with TRIzol
(Invitrogen, Carlsbad, CA) according to manufacturer’s instructions, and after
purification, total RNA was reverse transcribed with RETROscript (Ambion, Austin, TX)
following producer’s recommendations. Real-time PCR was effected with SYBR Green
Supermix (Bio-Rad, Hercules, CA) on an iCycler iQ Real Time PCR Detection System
(Bio-Rad, Hercules, CA). Primers were designed with the NCBI online database
(www.ncbi.nlm.nih.gov) and Primer3 (http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi). Primer pair sequence specificities were confirmed via
BLAST (Table 1), and all primers were obtained from MWG Oligo Synthesis (High
Point, NC). Real-time PCR was performed in 96-well optical plates with 0.05μM each of
forward and reverse primers, cDNA from 2μg RNA input (diluted 1:50), and 12.5μL
Supermix. Target genes were amplified through the following thermocycling program:
95ºC for 3’, 40 X 15‖ PCR cycles at 95ºC, 60ºC for 1’, and 55ºC for 1’. At the end of the
program, 80 repeats of 15‖ each accompanied by a temperature ramp of 0.5ºC/repeat

31
Table 1. Primer sequences (GenBank/NCBI) used in real-time PCR
------------------------------------------------------------------------------------------------------------------------------------------------------Primer ID
Primer Sequence 5’—3’
Accession No.
Length, nt
------------------------------------------------------------------------------------------------------------------------------------------------------18S

Fwd: AAACGGCTACCACATCCAAG
Rev: GGCCTCGAAAGAGTCCTGTA

M11188

76

5HT1A

Fwd: TGTTGCTCATGCTGGTTCTC
Rev: CCGACGAAGTTCCTAAGCTG

NM 012585

76

5HT1B

Fwd: CTGGTGTGGGTCTTCTCCAT
Rev: GTTCACAAAGCAGTCCAGCA

NM 022225

84

5HT2A

Fwd: CTGCTGGGTTTCCTTGTCAT
Rev: ATCCAGATCGCACAGAGCTT

NM 017254

93

BDNF

Fwd: AGAGATCCAGCCCTGAGACA
Rev: TCACCACATGGAAGGGTCTT

NM012513.3

98

MAP2

Fwd: ACGTTCGCTTGAAAAGGAGA
Rev: CATGACGTTGATTCGTTTGG

NM013066.1

89

SPN

Fwd: GCAGGATCCAAGTGAACGAT
Rev: CGGTTTGGTGTTCCTAAGCA

NM

96

GHR

Fwd: CCTGATCCGCCCATTGGCCT
Rev: GCGGTGGCTGCCAACTCACT

NM017094

76

MEL1A

Fwd: GAGCGGGGTAAGGGGCAGGA
Rev: AGTGCCCAGCTCTGCTTGCG

NM053676

82

MEL1B

Fwd: CCGAGCCTGCAGTCAGTGGC
Rev: GGGCACCAAGGCCACCAGAG

NM001100641

76

-------------------------------------------------------------------------------------------------------------------------------------------------------Final concentration of each primer was 1μM
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were performed during which dissociation curve data were collected to verify that only
target sequences were amplified.
The following genes were amplified from hippocampus-derived cDNA: three
serotonin (5-hyroxytryptamine or 5HT) receptor subtypes (5HT1A, 5HT1B, and
5HT2A), brain-derived neurotrophic factor (BDNF), microtubule-associated protein 2
(MAP2), spinophilin (SPN), melatonin receptor subtypes 1A and 1B (MEL1A and
MEL1B), and growth hormone receptor (GHR). Each gene was co-amplified with a
standard housekeeping gene, 18S ribosomal RNA, to control for pipetting error.
A real-time PCR was conducted for each primer pair in which cDNA samples
were substituted with dH20 to verify that exogenous DNA was not present. Additionally,
2μg of RNA isolated by the procedure described above was substituted for cDNA in a
real time PCR reaction to confirm that there were no genomic DNA contaminants in the
RNA samples. Both negative controls showed no amplification after 35 cycles.
Computer-calculated cycle numbers at which amplified DNA surpassed
fluorescence threshold were normalized and contrasted to determine relative gene
expression across treatment groups. Low cycle numbers signified higher initial amounts
of cDNA or greater gene expression. All samples were run in triplicate, and threshold
values were averaged to determine cycle threshold (CT) values. Change in threshold
(dCT) was calculated for each sample by subtracting co-amplified 18s CT values from the
CT values for genes of interest.
For graphs, the group with the highest mean dCT value (lowest gene expression)
per amplified gene target was set to zero and the mean dCT values of the other three
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groups were set relative to this calibrator (ddCT). The ddCT values were calculated as
powers of 2 (2ddCT), to account for the exponential doubling of the polymerase chain
reaction.

Statistical Analysis

Growth data over time were averaged by litter, and linear regression analysis was
performed by comparison of full and reduced models for body mass and food intake by
treatment with family-wise Bonferroni correction (Minitab 15 Statistical Software, State
College PA). Comparisons of group-by-group reduced and full models were also
performed with family-wise and post hoc Bonferroni corrections.
Anatomical measures and most behavioral measures were compared first using
one-way ANOVA for control, melatonin, and luzindole animals followed by multiple
comparisons with Bonferonni post hoc analysis (SPSS 16.0, Chicago, IL). Morris water
maze data were analyzed with nonlinear mixed effects modeling via the method of
Young et al. (2008) (R, R Foundation for Statistical Computing, Vienna, Austria). Gene
expression data were compared by Kruskal-Wallis analysis followed by group-by-group
Wilcoxon analysis with Bonferroni correction (SPSS). Ideally, studies examining
prenatal effects on litters should use litter averages as the sample unit (Krinke 2000).
Given that the present data include only 3-4 litters per treatment group, it was decided to
use individual young as sample units for most measures in this report. Our final study for
publication from this data will include at least 8 litters per treatment group. For all
measures, statistical significance was set to P < 0.05.
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RESULTS

Effects of Altered Prenatal Melatonin Signaling on Litter Size, Litter Composition,

Growth, and Feeding Patterns

The effects of administration of vehicle, 5 mg/kg melatonin, or 5mg/kg luzindole
to pregnant dams from days 14-18 of gestation on litter size, litter sex composition, and
birth body mass of male and female pups are indicated in Table 2. Treatment had no
significant effect on litter size, although this measure was approaching significance
[F(2,8)=4.078, P=0.060] for a reduction in litter size for the melatonin-treated dams
compared to luzindole-treated dams [P=0.085]. No significant difference was found
between litters for male to female pup ratio [F(2,8)=0.333, P=0.726] or for average male
body mass [F(2,8)=0.511, P=0.618] and average female body mass [F(2,8)=0.332, P=0.727]
per litter.
Body mass gain and food intake for male rat litters treated prenatally with vehicle,
melatonin, or luzindole is shown in Figure 6. The body mass curve for litters treated
prenatally with melatonin was significantly different from litters treated prenatally with
vehicle or luzindole [Overall reduced model to overall full model [F(6,174)=5.0564,
P=0.00075]; reduced control and melatonin model to full control and melatonin model
[P=0.00171]; reduced control and luzindole model to full control and luzindole model
[P=1.00]; reduced melatonin and luzindole model to full melatonin and luzindole model
[P=0.01084]]. In addition, prenatal treatment was not found to have a significant effect
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Table 2. Litter size, ratio of male pups to female pups per litter, and average body mass of male and female
pups per litter for dams treated with vehicle, 5 mg/kg melatonin, or 5 mg/kg luzindole during days 14-18 of
gestation
---------------------------------------------------------------------------------------------------------------------------------------------------------------________

Litter Size
(Pups)

Male Pups/
_____Female Pups

Average Male Mass
Average Female Mass
_______(g/pup per litter)__________(g/pup per litter) ___

Control (CON)

14.3 ± 0.9

0.88 ± 0.07

12.7 ± 1.0

12.3± 1.2

Melatonin (MEL)

11.8 ± 0.6

0.9 ± 0.2

13.5 ± 0.9

12.8 ± 1.0

Luzindole (LUZ)

14.8 ± 0.9

1.1 ± 0.2

11.8 ± 1.5

11.5 ± 1.3

CON-MEL-LUZ

P=0.060

P=0.726

P=0.618

P=0.727

CON-MEL

P=0.197

P=1.00

P=1.00

P=1.00

CON-LUZ

P=1.00

P=1.00

P=1.00

P=1.00

MEL-LUZ

P=0.085

P=1.00

P=1.00

P=1.00

________________________________________________________________________________________________
Values are means ± SEM. Differences between groups (control-melatonin-luzindole) were determined using one-way
ANOVA. Significant differences were further analyzed using multiple comparison tests and Bonferroni post hoc analysis.
Values for litters from dams treated with vehicle, 5 mg/kg melatonin, or 5 mg/kg luzindole during days 14-18 of gestation
were compared. *** P < 0.001, ** P < 0.01, * P < 0.05 means are significantly different from control.
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Figure 6. Average body weights (a) and food intake (c) of male rats treated
prenatally with vehicle, melatonin, or luzindole. Weight and food intake of 11 litters
[Control n=3, Melatonin n=4, Luzindole n=3] was averaged from weaning at postnatal
day (PD) 21 to after PD120. Overall reduced and full regression models with familywise Bonferroni corrections were fit to data and compared for significance followed by
group-by-group comparisons with additional group-by-group Bonferroni corrections
(b,d). Litters treated with prenatal melatonin were found to have body mass curves
significantly different from controls and luzindole-treated litters [[** P<0.01],
[*P<0.05]]; however, prenatal treatment was not found to have a significant effect on
food intake.
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Reduced : BodyMass  173  11.3( PD)  0.0464( PD) 2
r 2  0.981

Full : BodyMass  162  10.9( PD)  0.0442( PD) 2
 14.7( MEL)  0.794( MEL)( PD)  0.00433( MEL)( PD) 2
 16.3( LUZ )  0.446( LUZ )( PD)  0.00158( LUZ )( PD) 2
r 2  0.984
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Reduced : FoodIntake  16.2  1.48( PD)  0.0160( PD) 2  0.000055( PD)3
r 2  0.766

Full : FoodIntake  16.2  1.43( PD)  0.0153( PD) 2  0.000052( PD)3
 3.57( MEL)  0.055( MEL)( PD)  0.00055( MEL)( PD) 2  0.000003( MEL)( PD)3
 2.93( LUZ )  0.167( LUZ )( PD)  0.00219( LUZ )( PD) 2  0.000008( LUZ )( PD)3
r 2  0.789
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on food intake curves of litters [Overall reduced model to overall full model
[F(8,154)=2.0693, P=0.3832].
As summarized in table 3, prenatal treatment had no significant impact on
percentage body fat [F(2,61)=0.157, P=0.855], left hippocampus mass [F(2,60)=0.902,
P=0.411], right hippocampus mass [F(2,60)=0.432, P=0.651], or left hippocampus mass to
right hippocampus mass ratio [F(2,60)=0.105, P=0.901].

Effects of Altered Prenatal Melatonin Signaling on Adult Behavior

Exposure to melatonin or luzindole in utero did not have a significant impact on
adult male rat behavior in the forced swim test (Figure 7). Prenatal treatment did not
affect total distance traveled [F(2,58)=0.887, P=0.418], number of fecal boli produced
[F(2,58)=0.593, P=0.556], time spent immobile [F(2,58)=0.570, P=0.569], or number of
immobile episodes [F(2,58)=0.1864, P=0.427]. Although the results for the effects of
prenatal treatment on turn preference were not significant, a trend was indicated
[F(2,58)=2.826, P=0.067] for a greater right turn preference for male rats exposed to
melatonin prenatally [p=0.066].
The impact of prenatal treatment on adult male rat behavior in the open field test
was dramatic (Figure 8). Although treatment did not have a significant impact on time
spent in the center of the arena [F(2,61)=0.769, P=0.468] or turn preference [F(2,61)=0.681,
P=0.510], significant effects were observed for total distance traveled [F(2,61)=4.586,
P=0.014], time inactive [F(2,61)=4.920, P=0.010], time rearing [F(2,61)=4.175, P=0.020],
time grooming [F(2,61)=5.470, P=0.007], number of corner entries [F(2,61)=4.938,
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Table 3. Percent body fat, left and right hippocampus mass, and ratio of left hippocampus mass to right
hippocampus mass at sacrifice for male rats treated prenatally with vehicle, melatonin, or luzindole
---------------------------------------------------------------------------------------------------------------------------------------------------------------Percent Body Fat
Left Hippocampus
Right Hippocampus Left Hippocampus/Right
________
(fat/body mass) _______Mass (mg)____________Mass (mg)_______Hippocampus Mass___
Control (CON)

3.54 ± 0.16

75 ± 3

74.8 ± 1.8

1.01± 0.04

Melatonin (MEL)

3.4 ± 0.3

76 ± 3

75 ± 2

1.03± 0.03

Luzindole (LUZ)

3.46 ± 0.14

72.4 ±1.3

72.8 ± 1.5

1.01±0.03

CON-MEL-LUZ

P=0.855

P=0.411

P=0.651

P=0.901

CON-MEL

P=1.00

P=1.00

P=1.00

P=1.00

CON-LUZ

P=1.00

P=1.00

P=1.00

P=1.00

MEL-LUZ
P=1.00
P=0.606
P=1.00
P=1.00
________________________________________________________________________________________________
Values are means ± SEM. Differences between groups (control-melatonin-luzindole) were determined using one-way
ANOVA. Significant differences were further analyzed using multiple comparison tests and Bonferroni post hoc analysis.
Values at sacrifice for male rats treated with vehicle, melatonin, or luzindole prenatally were compared. Percent body fat
was found by summing masses of abdominal, gonadal, and retroperitoneal fat deposits in grams and dividing by total
body mass in grams.*** P < 0.001, ** P < 0.01, * P < 0.05 means are significantly different from control.
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Figure 7. The effects of prenatal melatonin or luzindole on adult male rat behavior
in the forced swim test. Prenatal treatments were not found to have a significant effect
on total distance traveled (a), fecal boli (b), immobile time (c), immobile episodes (d),
and turn preference (e); however, turn preference was approaching significance
[F(2,58)=2.826, P=0.067] with rats exposed prenatally to melatonin treatment showing a
trend toward increased preference for turning right compared to controls [P=0.066]. Data
are expressed as means + SE [Control n=16, Melatonin n=17, luzindole n=28]. Statistical
differences were determined using one-way ANOVA for the effects of prenatal treatment
followed by multiple comparison testing using Bonferroni post hoc analysis.
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Figure 8. The effects of prenatal melatonin or luzindole on adult male rat behavior
in the open field test. Prenatal treatment did not have a significant impact on time spent
in center of arena (e) or turn preference (h). Prenatal treatment did significantly affect
total distance traveled (a), inactive time (b), rearing time (c), number of corner entries (f),
and fecal boli (g) [*P<0.05] in addition to grooming time (d) [**P<0.01]. Data are
expressed as means + SE [Control n=18, Melatonin n=18, luzindole n=28]. Statistical
differences were determined using one-way ANOVA for the effects of prenatal treatment
followed by multiple comparison testing using Bonferroni post hoc analysis.
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P=0.010], and number of fecal boli produced [F(2,61)=4.070, P=0.022]. In particular, rats
exposed to luzindole traveled significantly less distance than controls [P=0.013] and
produced significantly more fecal boli [P=0.033]. In addition, rats treated with luzindole
prenatally spent significantly more time inactive [P=0.023 control, P=0.050 melatonin]
and grooming [P=0.029 control, P=0.018 melatonin] and made significantly fewer entries
to the corners [P=0.042 control, P=0.026 melatonin] compared to controls and melatoninexposed animals. Moreover, animals subjected to melatonin prenatally exhibited rearing
behavior for a significantly greater duration than control [P=0.045] and luzindole rodents
[P=0.036].
In the elevated plus maze, adult male rat behavior was differentially altered by
prenatal treatment (Figure 9). Prenatal treatments had no significant effects on total
distance traveled [F(2,60)=1.467, P=0.239], time inactive [F(2,60)=1.625, P=0.205], time
rearing [F(2,60)=0.005, P=0.995], percentage of open arm entries number [F(2,60)=0.0822,
P=0.444], percentage of closed arm entries [F(2,60)=1.407, P=0.253], percentage of central
platform entries [F(2,60)=2.000, P=0.144], and number of fecal boli [F(2,60)=0.396,
P=0.675]. However, rats exposed to prenatal melatonin showed a significantly stronger
right turn preference [F(2,60)=4.761, P=0.012] than luzindole rodents [P=0.012] with a
trend toward an augmented right turn preference relative to controls [P=0.080]. In
addition, a trend was observed for grooming time [F(2,60)=3.101, P=0.052] such that
luzindole-treated animals approached increased grooming time [P=0.058] in relation to
melatonin-exposed subjects.
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Figure 9. The effects of prenatal melatonin or luzindole on adult male rat behavior
in the elevated plus maze. Prenatal treatment did not have a significant impact on total
distance traveled (a), time spent inactive (b), time spent rearing (c), percentage open arm
entries (e), percentage closed arm entries (f), percentage central platform entries (g) or
number of fecal boli produced (h). Grooming time [F(2,60)=3.101, P=0.052] was
approaching a significant effect for prenatal treatment such that luzindole animals
displayed a trend toward increased grooming time [P=0.058] relative to melatonin
subjects. Rats exposed to melatonin prenatally displayed a significantly stronger right
turn preference than luzindole rodents [*P<0.05] (i). Data are expressed as means + SE
[Control n=17, Melatonin n=18, luzindole n=28]. Statistical differences were determined
using one-way ANOVA for the effects of prenatal treatment followed by multiple
comparison testing using Bonferroni post hoc analysis.
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Prenatal treatment also significantly changed performance in the learning phase of the
Morris water maze but not in the memory phase (Figure 10). Overall nonlinear mixed
effects modeling revealed a significant difference for the slope of the learning curve
[F(2,263)=12.52689, P<0.0001] but not for the intercept [F(2,263)=2.07505, P=0.1276] as a
result of prenatal treatment. T-test comparison by treatment groups with Bonferroni
corrections revealed that rats administered luzindole prenatally had learning curves with
slopes significantly reduced compared to controls [P=0.0015] and melatonin-treated
animals [P<0.0003]. No significant differences were found for latency to platform
[F(2,61)=0.231, P=0.794], mean distance from platform [F(2,61)=0.153, P=0.858], time
spent in memory region [F(2,61)=0.405, P=0.669], total distance traveled [F(2,61)=0.775,
P=0.465], or turn preference [F(2,61)=0.857, P=0.429].

Effects of Altered Prenatal Melatonin Signaling on Hippocampal Gene Expression

Due to outliers and observable skew in the data sets, nonparametric KruskalWallis tests were used to analyze gene expression data (Figure 11). Analysis of gene
expression during two distinct time periods (0000 hr vs. 1200 hr) failed to produce a
significant difference in circadian expression of the genes examined (data not shown),
although MAP2 expression displayed circadian behavior closest to significance [P=
0.1547]. In contrast, Kruskal-Wallis analysis revealed a significant effect of prenatal
treatment on expression of BDNF [P=0.043] and MAP2 [P=0.048]. Group-by-group
Wilcoxon comparisons with Bonferroni corrections found a significant increase in
expression of BDNF in melatonin rats compared to controls [P=0.0425], but the increase
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Figure 10. The effects of prenatal melatonin or luzindole on adult male rat behavior
in the Morris water maze. Linear mixed effects modeling showed that prenatal
treatment produced a decrease in slope of the learning curve for luzindole-treated animals
relative to controls [**P<0.01] and melatonin-treated animals [***P<0.001] but had no
significant impact on intercept of the learning curve (a). No significant effects of
prenatal treatment were observed in the memory phase of the test (b-f). Data are
expressed as means + SE [Control n=18, Melatonin n=18, luzindole n=28]. Statistical
differences for the learning phase were determined by nonlinear mixed effects modeling.
Statistical differences for the memory phase were determined using one-way ANOVA for
the effects of prenatal treatment followed by multiple comparison testing using
Bonferroni post hoc analysis.
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Figure 11. The effects of prenatal melatonin or luzindole on adult male rat
hippocampal gene expression. Relative cycle number to fluorescence for hippocampal
cDNA during real-time PCR with primers for 5HT1A, 5HT1B, 5HT2A (b); BDNF,
MAP2, spinophilin (SPN) (d); and growth hormone receptor (GHR), MEL1A, MEL1B
(f); with 18s is indicated in representative kinetics curves. Relative gene expression for
all genes assayed is also indicated (a,c,e). Prenatal treatment had a significant effect on
expression of BDNF and MAP2 [*P<0.05] and produced a trend toward significance for
MEL1A expression [P=0.078]. In particular, a significant increase in expression of
BDNF in rats treated prenatally with melatonin relative to controls [*P<0.05] was found.
Data are expressed as means + SE [Control n=18, Melatonin n=18, luzindole n=28].
Statistical differences were determined using Kruskal-Wallis for the effects of prenatal
treatment followed by group-by-group Wilcoxon comparisons with Bonferonni
corrections.
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in expression of BDNF in melatonin animals compared to luzindole animals was
not significant [P=0.1317]. In addition, group-by-group comparison revealed a trend
toward increased expression of MAP2 in luzindole rats compared to controls [P=0.0526].
Finally, a trend for a treatment effect on MEL1A expression [P=0.078] was also
observed.

DISCUSSION

Our study was designed to test the effects of altered prenatal melatonin signaling
on growth patterns, behavior, and hippocampal gene expression in adult male rats. The
limited existing research on the postnatal effects of altered prenatal melatonin signaling
precludes a definitive conclusion; however, data from a series of diverse studies on the
functions of melatonin in general provide a context for our findings.

Melatonin and Body Growth

As predicted, prenatal melatonin had a significant impact on growth patterns of
offspring. An upward shift in growth curve and accelerated growth was observed for
melatonin-treated animals compared to luzindole-treated animals and controls. These
alterations were not accompanied by a change in body fat at sacrifice which suggests that
this difference was not the result of increased fat deposition. Growth hormone has been
shown to increase muscle and skeleton mass and to reduce fat mass in female pigs
(Sørensen et al. 1996), and growth hormone administration to 19- to 21-month-old
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Sprague-Dawley rats induced greater protein synthesis (Sonntag et al. 1985). Thus, it is
possible that the growth changes measured in our animals may be due to alterations in
growth hormone secretion.
The direction of the change in growth patterns, however, is difficult to interpret
given the contradictory findings in the literature. Administration of melatonin (4 μg/mL)
in drinking water for 12 weeks to adult Sprague-Dawley rats produced sex-dependent
metabolic effects (Bojková et al. 2008). In particular, in adult males, exposure to excess
melatonin reduced body weight, liver glycogen, and serum insulin and increased
concentrations of corticosterone, serum and heart muscle cholesterol, heart muscle
phospholipids, and indicators of oxidative stress. Interestingly, the increase in growth
hormone secretion elicited by administration of serotonin (10 mg/kg) to 80-day-old
Wistar rats was blocked by concomitant administration of melatonin (80 mg/kg) (Smythe
et al. 1973). Similar antagonistic effects for both melatonin and serotonin on growth
hormone secretion were also observed in 21-28-year-old human male subjects (Smythe et
al. 1974 b). Thus, it appears that melatonin may mediate reduction in growth hormone
secretion and body mass in adult rats.
However, melatonin’s effect on growth may be different when administered
during prenatal development or lactation. Injection of meadow vole Microtus
pennsylvanicus dams with 10 μg melatonin per animal daily during pregnancy reduced
offspring weight in both sexes and delayed sexual development only in male offspring
(Lee et al. 1989). In contrast, melatonin treatment during lactation increased body
growth from postnatal day 21 until sacrifice at postnatal day 49 for males and females. In
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the male rat, pineal and serum melatonin levels at the middle of the dark phase of the
circadian cycle were found to rise during postnatal days 1 to 9, remain high during
postnatal days 11 to 17, and lower after day postnatal day 21 (Tang et al. 1988).
Moreover, the drop in melatonin levels after postnatal day 21 was found to be
independent of weaning. Although we altered only prenatal melatonin levels in our
experimental animals, we had hypothesized that treatments would permanently alter
function of the circadian circuit causing increased endogenous melatonin production
postnatally in melatonin-treated animals and reduced melatonin secretion postnatally in
luzindole treated animals. The observed augmentation of growth in our melatonin-treated
rats may not be consistent with immediate effects of prenatal treatment on growth
patterns of offspring but may be consistent with augmented postnatal function of the
circadian circuit. In particular, our data may suggest increased melatonin levels in
offspring during the period of lactation as a result of prenatal melatonin treatment.

Melatonin and Behavior

As predicted, prenatal treatments in our study produced differential behaviors in
adult offspring. These differences are not fully consistent with existing literature since
increases or decreases in melatonin levels in adult rodents produce differential behaviors
based on experimental design. For example, depression of locomotor activity in adult
male golden hamsters was observed after intraperitoneal administration of at least 30 μg
melatonin/kg for 5 days (Golombeck et al. 1991). This effect on behavior was found to
be lowest at midnight and could be blunted by administration of a benzodiazepine. A
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reduction in locomotor activity, rears, and entries into the unfamiliar zone of the free
exploratory test was also observed in adult C3H/He mice (Kopp et al. 1999). However,
this change in behavior was measured in animals treated with 10 mg melatonin/kg per
day at the beginning of the dark phase during and immediately after a 3-week stress
period and then exposed to a chronic mild stress procedure.
Adult melatonin treatment has also been shown to elicit differential behavioral
patterns by sex. Administration of melatonin (4 μg/mL) in drinking water for two weeks
was associated with an increase in climbing in the forced swim test in thirteen-month-old
Long Evans male rats (Brotto et al. 2000). However, both treated and control females
displayed augmented activity in both the forced swim test and open field test compared to
males. Among the females studied, melatonin-exposed animals exhibited increased
immobility on the first day of the forced swim test. This study also showed that
melatonin exposure was associated with increased ambulation in the open field test and
reduced swimming in the forced swim test in both sexes. No significant change in
behavior in the forced swim test was observed for either treatment in our study compared
to the significant changes observed by Brotto et al. Moreover, the significant change in
behavior of adult male animals exposed prenatally to melatonin and tested in the open
field test in our study is different from the changes in response to adult melatonin
treatment in the Golombek et al., Kopp et al., and Brotto et al. studies. More specifically,
our melatonin-exposed animals displayed augmented rearing compared to animals treated
with luzindole in utero or controls but not increased distance traveled relative to controls.
Given the increased ambulation but not rearing in the open field test of animals treated
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with melatonin in adulthood in the Brotto et al. study and the reduction in locomotor
activity by Golombek et al. and Kopp et al., we suggest that prenatal and postnatal
melatonin changes may elicit differential behavioral effects in adult animals.
Melatonin not only produces differential effects by sex but also by the receptor
subtype via which it elicits signaling. MEL1A receptor knockout mice of both sexes
displayed impaired sensorimotor gating as evidenced by the prepulse inhibition test (Weil
et al. 2005). These mice also showed decreased preference for the center of the arena in
the open field test. In addition, they spent more time immobile in the forced swim test.
Female wild-type mice showed greater locomotor activity than males in the open field
test, but this difference between sexes did not exist in knockout mice. In another study,
4- to 5-week-old C3H/HeN mice administered melatonin (30 mg/kg) did not show a
significant change in behavior in the forced swim test while luzindole (30 mg/kg)
reduced immobility time in the forced swim test with a greater effect at midnight than at
noon (Dubocovich et al. 1990). Moreover, administration of 30 mg/kg melatonin with 10
mg/kg luzindole blunted the effects of luzindole on behavior. In subsequent study using
MEL1A-knockout and MEL1B-knockout C3H/HeN mice, it was found that this effect of
luzindole on forced swim test behavior was mediated via the MEL1B receptor (Sumaya
et al. 2005). Since no effects of treatment were observed in the forced swim test for our
subjects, our data suggest that activity of MEL1B receptors are not significantly affected
by treatment. In contrast, the augmented fear response of luzindole animals in the open
field test as indicated by increased time inactive suggest a possible role for MEL1A
receptor dysregulation in these animals. Interestingly, rats exposed prenatally to
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luzindole in our study outperformed both melatonin-treated and control animals in the
learning phase of the forced swim test by finding the platform more quickly. Since
MEL1B receptor knockout mice displayed impaired spatial learning in the Morris water
maze (Larson et al. 2006), our data from luzindole-exposed offspring in the learning
phase of the forced swim test may also preclude involvement of MEL1B receptors in the
behavioral differences observed in our subjects.
In addition to postnatal changes in melatonin signaling via administration of
melatonin agonists or antagonists in adulthood and lifelong changes in melatonin
signaling by receptor knockout, prenatal alterations of melatonin signaling have also been
found to impact adult behavior. Maternal pinealectomy of Siberian hamsters produced
increased immobility in the forced swim test and rearing behavior in the open field test of
adult male offspring (Workman et al. 2008). Moreover, this study found that postnatal
pinealectomy of adult males augmented locomotor activity in the open field test. Our
results, however, are inconsistent with this study. No significant differences in forced
swim test behavior in our prenatally animals were observed compared to the increased
learned helplessness in response to reduced prenatal melatonin signaling in the Workman
et al. study. In addition, melatonin-treated animals in our study displayed increased
rearing and locomotor activity in the open field test relative to luzindole-treated animals.
Luzindole treatment would be expected to have reduced effectiveness of melatonin
signaling during early development of our rats. Since the subjects in the Workman et al.
study showed increased locomotor activity in response to reduced melatonin signaling
following postnatal pinealectomy, it is possible that prenatal and postnatal effects of
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melatonin on signaling are significantly different. Moreover, the use of pinealectomy or
removal of endogenous melatonin in their study versus exogenous hormone or hormone
antagonist treatment in ours may have produced differential effects. Species differences
may also be important in this case.
Additional studies designed to alter the intrauterine environment included
melatonin administration to spontaneously hypertensive rat (SHR) dams. SHR animals
are considered a model of attention deficit hyperactivity disorder (Sagvolden 2000)
which is associated with heightened locomotor activity. SHR dams given water
containing melatonin (20 μg/mL) during gestation and lactation were found to have
offspring that displayed reduced locomotor activity and rearing behavior as compared to
control SHR offspring (Kim et al. 2002). Our findings differ from the Kim et al. study in
that prenatal melatonin treatment reduced locomotor activity in the forced swim test in
their animals while our animals exposed to melatonin in utero showed no significant
difference from controls. In addition, their animals also displayed reduced locomotor
activity in the open field test in response to prenatal treatment with melatonin while our
melatonin animals showed increased locomotor activity. However, since they used a
strain of rats considered to be a model of a psychiatric disorder, it is possible that their
animals responded differently to melatonin treatment than wild type rats.
Animals treated prenatally with luzindole in our study displayed significantly
greater grooming than melatonin-treated animals and controls. Previous studies suggest
that increased grooming behavior may be a result of increased stress response in these
animals. For example, administration of the corticotrophin releasing factor 1 (CRF1)
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receptor agonist MJL-1-109-2 (1 nM) to adult male Wistar rats produced increased
freezing, grooming, and mounting behaviors (Zhao et al. 2007). Administration of CRF1
to adult male Wistar rats also induced an increase in hippocampal free corticosterone
levels and a reduction in serotonin (de Groote et al. 2005). Further data collection will
include radioimmunoassay analysis of serum for basal corticosterone levels in our
animals.
In contrast to our luzindole-exposed adult offspring, animals treated prenatally
with melatonin in our study displayed significantly increased rearing behavior. A first
review of evidence for a role of the septo-hippocampal system in rearing behavior
concluded, however, that the role of the hippocampus in exploratory rearing behavior is
still poorly understood (Lever et al. 2006). The authors cite various lines of evidence
implicating the involvement of projections from the dentate gyrus to the CA3 region of
the hippocampus and also importance of the CA1 region in rearing behavior in reference
to spatial learning, but admit that the specific functions of these regions are highly
context dependent. Thus, the increased rearing behavior of animals exposed to melatonin
prenatally in our study suggests a potential role for prenatal melatonin in adult
hippocampal function.
Interestingly, in our melatonin-exposed offspring, a significant right turn
preference was observed in the elevated plus maze with a trend toward significance in the
forced swim test. A stronger right-turn preference was also found in adult Long-Evans
hooded rats in response to neonatal novelty (Tang et al. 2003). Moreover, these animals
showed increased social memory and lower basal plasma corticosterone levels compared
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to controls after neonatal novelty exposure. Abnormal brain lateralization has also been
associated with autism (Escalante-Mead et al. 2003) and schizophrenia (Sommer et al.
2001) in humans. In our study, measurements of left hippocampal mass compared to
right hippocampal mass suggest a slight increase in animals treated prenatally with
melatonin; however, the method of measurement may have been too imprecise to detect
significant mass differences. In addition, other studies suggest that volume
measurements are preferred to those of mass. Thus, additional procedures, such as
staining and sectioning of brain tissue, may be required to observe possible lateralization
differences in additional cohorts of rats reserved for this purpose. Given the potential
importance of brain lateralization in adult psychopathology, further research to confirm a
role for melatonin in brain lateralization is warranted.

Melatonin and Gene Expression
Our molecular data suggest a connection between prenatal melatonin signaling
and adult hippocampal gene expression. Moreover, evidence in the literature also
supports a significant molecular impact of maternal melatonin levels on offspring. For
example, pups of pinealectomized Wistar rat dams displayed reduced expression of
melatonin receptors in their brains at postnatal day 9 (Zitouni et al. 1995). MEL1A
receptor concentrations were reduced and clock gene expression oscillations were altered
in the SCN of capuchin monkey fetuses of pinealectomized mothers, and the effect of
pinealectomy on these variables could be ameliorated by melatonin administration
(Torres-Farfan et al. 2006).
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In our study, augmentation of prenatal melatonin signaling significantly increased
adult hippocampal BDNF expression in adult offspring. Recent studies from other in
vivo models have also found links between melatonin receptor signaling and BDNF
expression. Cerebellar granule cells from 5-day old MEL1B knockout CH3 mice showed
increased expression of BDNF in response to melatonin administration in vivo and in
vitro compared to those from wild-type and MEL1A-knockout mice (Imbesi et al. 2008
a). In addition, nanomolar concentrations of the melatonin receptor agonist, ramelteon,
increased expression of BDNF protein without increasing mRNA levels in cerebellar
granule cells from all MEL1A-knockout, MEL1B-knockout, and control mice (Imbesi et
al. 2008 b).
Results from in vitro cell culture studies suggest that melatonin regulates the
expression of its own receptors. For example, in CHO cell lines expressing high levels of
MEL1A receptors, a significant reduction in these receptors at the cell surface was
detected 1 hour after treatment with melatonin, but total cellular concentration of the
MEL1A receptor was unaffected (Kokkol et al. 2007). In contrast, this same study found
that CHO cell lines expressing high levels of melatonin MEL1A receptors decreased total
cellular MEL1A receptor concentrations in response to administration of luzindole at
both 1 and 72 hours after treatment, and expression at the cell surface was increased at 72
hour after treatment. Additional studies have shown that MEL1A receptors are also
expressed in the immortalized C17.2 dopaminergic neural stem cell line, and
administration of melatonin to these cells increased release of glial-cell derived
neurotrophic factor (Niles et al. 2004). A later study showed that melatonin treatment of
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these cells—which do not express MEL1B receptors—promoted neurite outgrowth,
increased expression of the neural stem cell marker nestin, histone deacetylases HDAC 3,
HDAC 5, and HDAC 7, and augmented histone H3 acetylation (Sharma et al. 2008).
Administration of valproic acid, a mood stabilizer, to rat C6 glioma cells for 24 hours
increased expression of MEL1A receptor mRNA and protein in a dose-dependent manner
and this increase in MEL1A receptor was associated with an increase in BDNF, GDNF,
and histone deacetylase (HDAC) mRNA levels (Castro 2005). In addition to influencing
the expression of neurotrophic factors, melatonin been found to inhibit apoptosis at the
mitochondrial level via MEL1A and MEL1B receptor signaling in U937 cells (Radogna
et al. 2008). Melatonin supplementation has also been shown to affect hippocampal cells
directly. For example, melatonin promoted survival of neural precursor cells from the
hippocampi of adult female C57BL/6 mice, and this effect could be diminished by
administration of luzindole (Ramírez-Rodríguez et al. 2009).
In addition to these cell culture studies, in vivo evidence suggests a role for
melatonin in hippocampal cell maintenance. Ramírez-Rodríguez et al. (2009) found that
administration of 8 mg/kg melatonin intraperitoneally to adult mice promoted survival of
neural precursor cells, but maturation and proliferation of these cells was unaffected. The
hippocampi of rats treated prenatally with melatonin in our study approached significance
for increased MEL1A expression relative to controls and luzindole-treated animals while
simultaneously displaying a significant increase in BDNF expression. Thus, our data
suggest an in vivo connection between MEL1A receptor signaling and BDNF expression
in the hippocampus and support a role for melatonin in hippocampal cell maintenance.
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Melatonin has been found to have various antioxidative properties that are
independent of its receptor-mediated effects (for reviews see Hardeland 2005; Ortiz et al.
2008). Pretreatment with 2 mg/kg melatonin subcutaneously was found to counteract
oxidative damage by methamphetamine in the neonatal Wistar rat prefrontal cortex,
nucleus accumbens, and dorsal striatum (Kaewsuk et al. 2009). These antioxidant
properties also extend to melatonergic drugs. Melatonin and related compounds have
been found to protect rat synaptosomal membranes from oxidative damage (Millán-Plano
et al. 2010). In the ABTS assay, both melatonin and luzindole at the concentration of 10
μM showed greater antioxidant capability compared to a similar concentration of ascorbic
acid (Mathes et al. 2008). Luzindole at a dose of 800 μM prevented lipid peroxidation
induced by iron and LPS in F344N rat brain tissue homogenates (Requintina et al. 2007).
The antioxidant properties of both melatonin and luzindole, however, suggest a
possible complication with our design. Given that the DMSO vehicle used has been
found to produce apoptosis of cells in the developing mouse brain at 0.3 mL/kg, the
lowest dose examined (Hanslick et al. 2009), it is possible that any deficits produced by
the vehicle can be ameliorated by either melatonin or luzindole. In our study, we used
DMSO at a concentration of 0.1 mL/kg per day. Although this dose is less than that used
by Hanslick et al. (2009), use of DMSO as a vehicle allows for the possibility that some
predicted deficits in either treatment group relative to controls may be hidden by the
antioxidant properties of the treatment.
Prenatal treatment in our study also altered mRNA expression for MAP2.
Previous studies suggest a role for MAP2 in the structure and function of hippocampal
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neurons. For example, hippocampal cells from MAP2 knockout mice cultured for 3
weeks displayed reduced dendritic length compared to cells from wild-type animals
(Harada et al. 2002). MAP2 expression in the hippocampus has been found to change in
response to learning tasks. In particular, MAP2 was down-regulated in the hippocampus
of adult male Wistar rats after exposure to the Morris water maze relative to controls
exposed to swimming or no testing 1 or 24 hours before sacrifice (Cavallaro et al. 2002).
Conversely, MAP2 protein and mRNA expression in the hippocampus was positively
correlated with learning and memory performance in the Morris water maze in male
Wistar rats exposed to cerebral hypoperfusion for 20 weeks (Liu et al. 2005). Our data
indicate that rats treated prenatally with luzindole displayed the greatest relative
expression of MAP2 mRNA and augmented performance in the learning phase of the
Morris water maze. Since the MAP2 protein is considered a marker of dendritic density,
a link between this protein and learning is logical. Given that the direction of change in
MAP2 expression is the same in both melatonin and luzindole-treatment groups, it is
possible that some of the treatment effects may be due to the antioxidant properties of the
drugs. It is also possible that hippocampal cell plasticity is increased in both groups for
different reasons. Examination of relative mRNA levels for additional genes—including
the marker of hippocampal neurogenesis, doublecortin (DCX) (Brown et al. 2003)—
would help to further explain these learning differences and is underway in our lab. It is
worth noting, however, that increased expression of MAP2 has been found in the
hippocampus of individuals with schizophrenia (Cotter et al. 2000) and thus can be a
marker of psychopathology.
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Although indications of an increase in anxiety-related behavior such as increased
inactive time and grooming in the open field test were identified in animals exposed to
luzindole prenatally, it is surprising that none of the 5HT receptor genes showed
differential expression in response to treatment. It is possible that the expression of these
serotonin receptors is altered only after a stressful challenge, and this possibility will be
studied in a future cohort of our prenatally exposed animals. Future research will also
entail radioimmunoassay of serum melatonin, growth hormone, and cortisol levels to
examine the effects of prenatal treatment on adult hormone secretion. Moreover, despite
a significant effect of prenatal treatment on MAP2 expression, no change in expression of
SPN was observed. Thus, our present data suggest that the prenatal treatments had an
impact on overall dendrite structure but not the fine structure of dendritic spines given the
localization of spinophilin to dendritic spines but MAP2 to entire dendrites. Also, despite
the effects of melatonin on growth curve shape, no significant differences in GHR
expression were observed.
Given that we have only extracted mRNA from the left hippocampi of our
subjects, we cannot make any conclusions regarding lateralization at the molecular level
at this time. In other studies, however, the hippocampus of rats showed differential
norepinephrine, serotonin, and choline uptake on the side opposite the direction of turn
preference in the T maze (Valdes et al. 1981). Comparisons of gene expression between
right and left hippocampi will be conducted.
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Model Incorporating the Circadian Circuit in Development

This study was based on four related hypotheses, although additional research
beyond this study will be necessary to validate all of them. First, maternal melatonin
secretion helps drive the growth and maintenance of neurons of the fetus. Some of this
effect results from cell signaling via cell membrane receptors that specifically bind
melatonin. Blockade of these receptors or increased binding of ligand to these receptors
results in greater or lesser growth of neurons. This altered neuron growth affects the
construction of the meshwork of circuits in the developing fetal brain. In addition to this
immediate effect on early brain development, changes to the fetal circuit meshwork
impact future brain growth by providing an abnormal scaffold for later cell migration,
growth, and connectivity.
Second, since melatonin receptors are found in high concentrations in the fetal
hypothalamus, early growth of the SCN is more markedly affected by prenatal melatonin
concentrations compared to other brain regions. Given that the SCN functions as the
circadian pacemaker, altering the development of this brain region permanently affects
the function of the circadian circuit of an organism. These permanent changes in the
circadian circuit result in physiological and behavioral changes in adult organisms
Third, since the hippocampus develops rapidly during a specific period in the
third trimester of pregnancy while other brain regions develop more gradually, this brain
region shows larger changes in response to altered prenatal melatonin levels in late
gestation than other brain regions. Because this brain region is particularly plastic
throughout development and adulthood, improper function of the circadian circuit

68
resulting in aberrant melatonin secretion compounds existing developmental aberrations
by influencing further postnatal growth, maintenance, and plasticity. As a result this
summation of prenatal and postnatal effects of prenatal melatonin on hippocampal
development, initial pathology of this brain region becomes more pronounced as the
brain develops through puberty and early adulthood.
Fourth, since circadian melatonin secretion regulates the release of other
hormones, permanently altering the circadian circuit causes various changes in circadian
physiology of neuroendocrine circuits. In particular, melatonin influences growth
hormone release. Since growth hormone is important in various aspects of growth,
metabolism, and brain function, changes in circadian growth hormone signaling may
cause subtle aberrations in these processes. In addition, because the circadian circuit and
the hippocampus also interact with the HPA axis, changes in these brain regions in
response to alterations of prenatal melatonin signaling will permanently alter HPA-axis
function.
Although these hypotheses are broad, they provide a framework for a model
involving the circadian circuit in brain development. Given the numerous interactions of
the circadian circuit and the HPA axis of mammals and the importance of variation in
function of both circuits over a 24-hour period, we designate the term
circadioneuroendocrine axis (CNE) axis. The CNE axis includes structures of both the
circadian circuit and HPA axis in addition to hormones released by the pituitary, pineal,
and other neuroendocrine glands which directly impact brain function and organismal
behavior in response to environmental stimuli. Use of this term stresses the necessity of
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investigating these circuits as a function of time. Such a framework is required for
integration of the litany of varied and often contradictory research already conducted in
the field of neuroscience. Moreover, future research will need to be conducted precisely
within such a framework to connect it to existing literature if a holistic understanding of
brain development and function is to be obtained.
From this terminology follows a name for our hypothesis regarding the role of the
CNE axis in brain development and psychopathology: the CNE-axis hypothesis of
psychopathology. According to this hypothesis, the magnitude, direction, timing, and
duration of disturbances of the CNE axis during development determine the resulting
psychiatric disorder. This hypothesis does not preclude genetic causation but does
provide for the incorporation of not only environmental stimuli but also the timing of
those stimuli relative to endogenous rhythms. Future research will be necessary,
however, to discover potential new and integrate existing known critical periods and
critical disturbances capable of producing outlying developmental trajectories.

PERSPECTIVES AND SIGNFICANCE

Although our study does not provide definitive support for any of the broad
hypotheses of our proposed model, our data do support the hypothesis that melatonin
signaling in utero disturbs neuroendocrine setpoints to produce differential growth,
behavior, and gene expression in a region of the brain in the male rat that is important in
human psychopathology. Because nocturnal rats (Mandera et al. 2003) secrete melatonin
in profiles that are comparable to those of diurnal organisms, signaling via melatonin
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receptors in rats is likely to produce different cellular responses compared to those found
in diurnal mammals. Comparative studies show that while melatonin exerts certain
differential effects between nocturnal and diurnal organisms, some of its actions may be
similar across species (López-Olmeda et al. 2006). Studies of melatonin functions in
multiple organisms allow for possible mechanisms in other species to be elucidated and
for the formulation of further research questions. Moreover, as the body of literature
regarding the developmental impacts of melatonin is built, current theoretical frameworks
of the circadian circuit and its effectors can be further amended to incorporate
interspecies variations.
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